Advanced stage III/IV melanoma patients with tumors expressing the MAGE-3 antigen were enrolled and treated with MAGE-3 peptides (HLA-A1/B35) loaded dexosomes from autologous DCs in conjunction with MAGE-3 class II peptides (DP04) or tetanus toxin class II epitopes for helper effects [82]. This evidence concerns the gene MAGEA3 and melanoma.